"Drug Design" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
| Descriptor ID |
D015195
|
| MeSH Number(s) |
E05.295.500 H01.158.703.007.675.500 H01.181.466.675.500
|
| Concept/Terms |
Drug Design- Drug Design
- Design, Drug
- Designs, Drug
- Drug Designs
Drug Modeling- Drug Modeling
- Drug Modelings
- Modeling, Drug
- Modelings, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Design".
Below are MeSH descriptors whose meaning is more specific than "Drug Design".
This graph shows the total number of publications written about "Drug Design" by people in this website by year, and whether "Drug Design" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2003 | 1 | 7 | 8 |
| 2004 | 2 | 3 | 5 |
| 2006 | 1 | 2 | 3 |
| 2007 | 3 | 10 | 13 |
| 2008 | 3 | 2 | 5 |
| 2009 | 2 | 3 | 5 |
| 2010 | 3 | 6 | 9 |
| 2011 | 0 | 8 | 8 |
| 2012 | 1 | 1 | 2 |
| 2013 | 3 | 1 | 4 |
| 2014 | 1 | 6 | 7 |
| 2015 | 2 | 4 | 6 |
| 2016 | 1 | 4 | 5 |
| 2017 | 1 | 3 | 4 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Design" by people in Profiles.
-
Cell-targeted vaccines: implications for adaptive immunity. Front Immunol. 2023; 14:1221008.
-
Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases. Int J Mol Sci. 2023 Aug 06; 24(15).
-
Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment. Am Soc Clin Oncol Educ Book. 2023 May; 43:e390084.
-
Molecular determinants of inhibition of the human proton channel hHv1 by the designer peptide C6 and a bivalent derivative. Proc Natl Acad Sci U S A. 2022 06 07; 119(23):e2120750119.
-
Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Eur J Med Chem. 2021 Nov 15; 224:113672.
-
Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model. Chem Commun (Camb). 2021 Jun 15; 57(48):5909-5912.
-
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
-
Structural basis for adhesion G protein-coupled receptor Gpr126 function. Nat Commun. 2020 01 10; 11(1):194.
-
Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2. Bioorg Med Chem Lett. 2019 08 15; 29(16):2136-2140.
-
Allosteric modulation of a human protein kinase with monobodies. Proc Natl Acad Sci U S A. 2019 07 09; 116(28):13937-13942.